Advertisement

Targeted Oncology

, Volume 14, Issue 2, pp 205–221 | Cite as

Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System

  • Emanuel RaschiEmail author
  • Alessandra Mazzarella
  • Ippazio Cosimo Antonazzo
  • Nicolò Bendinelli
  • Emanuele Forcesi
  • Marco Tuccori
  • Ugo Moretti
  • Elisabetta Poluzzi
  • Fabrizio De Ponti
Original Research Article

Abstract

Background

Immune checkpoint inhibitors (ICIs), including antibodies targeting cytotoxic T-lymphocyte associated protein 4 (CTLA4) and programmed cell death 1 or its ligand (PD1/PDL1), elicit different immune-related adverse events (irAEs), but their global safety is incompletely characterized.

Objective

The aim of this study was to characterize the spectrum, frequency, and clinical features of ICI-related adverse events (AEs) reported to the FDA Adverse Event Reporting System (FAERS).

Patients and methods

AEs from FAERS (up to June 2018) recording ICIs (ipilimumab, nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab) as suspect were extracted. Comprehensive disproportionality analyses were performed through the reporting odds ratio (ROR) with 95% confidence interval (95% CI), using other oncological drugs as comparison. An overview of systematic reviews (OoSRs) was also undertaken to identify irAEs with consistent positive associations.

Results

ICIs were recorded in 47,266 reports, submitted mainly by consumers receiving monotherapy with anti-PD1/PDL1 drugs. Three areas of toxicity emerged from both disproportionality analysis and the OoSRs (32 studies): endocrine (N = 2863; ROR = 6.91; 95% CI 6.60–7.23), hepatobiliary (2632; 1.33; 1.28–1.39), and respiratory disorders (7240; 1.04; 1.01–1.06). Different reporting patterns emerged for anti-CTLA4 drugs (e.g., hypophysitis, adrenal insufficiency, hypopituitarism, and prescribed overdose) and anti-PD1/PDL1 agents (e.g., pneumonitis, cholangitis, vanishing bile duct syndrome, tumor pseudoprogression, and inappropriate schedule of drug administration). No increased reporting emerged when comparing combination with monotherapy regimens, but multiple hepatobiliary/endocrine/respiratory irAEs were recorded.

Conclusions

This parallel approach through contemporary post-marketing analysis and OoSRs confirmed that ICIs are associated with a multitude of irAEs, with different reporting patterns between anti-CTLA4 and anti-PD1/PDL1 medications. Close clinical monitoring is warranted to early diagnose and timely manage irAEs, especially respiratory, endocrine, and hepatic toxicities, which warrant further characterization; patient- and drug-related risk factors should be assessed through analytical pharmaco-epidemiological studies and prospective multicenter registries.

Notes

Compliance with Ethical Standards

Funding

No sources of funding were used to assist in the preparation of this study. Authors at the University of Bologna (ER, EP, FDP) are supported by Institutional Research Funds (Ricerca Fondamentale Orientata).

Conflict of interest

Emanuel Raschi, Alessandra Mazzarella, Ippazio Cosimo Antonazzo, Nicolò Bendinelli, Emanuele Forcesi, Marco Tuccori, Ugo Moretti, Elisabetta Poluzzi, and Fabrizio De Ponti declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.

References

  1. 1.
    Clarke JM, George DJ, Lisi S, Salama AKS. Immune checkpoint blockade: the new frontier in cancer treatment. Targ Oncol. 2018;13:1–20.CrossRefGoogle Scholar
  2. 2.
    Martin-Liberal J, Hierro C, de Ochoa OM, Rodon J. Immuno-oncology: the third paradigm in early drug development. Targ Oncol. 2017;12:125–38.CrossRefGoogle Scholar
  3. 3.
    Hoos A. Development of immuno-oncology drugs—from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov. 2016;15:235–47.CrossRefGoogle Scholar
  4. 4.
    Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2:1346–53.CrossRefGoogle Scholar
  5. 5.
    Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749–55.CrossRefGoogle Scholar
  6. 6.
    Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158–68.CrossRefGoogle Scholar
  7. 7.
    Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714–68.CrossRefGoogle Scholar
  8. 8.
    Martins F, Sykiotis GP, Maillard M, Fraga M, Ribi C, Kuntzer T, et al. New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. Lancet Oncol. 2019;20:e54–64.CrossRefGoogle Scholar
  9. 9.
    Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016;13:473–86.CrossRefGoogle Scholar
  10. 10.
    Raschi E, Diemberger I, Cosmi B, De Ponti F. ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations. Intern Emerg Med. 2018;13:1–9.CrossRefGoogle Scholar
  11. 11.
    Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L, et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ. 2018;360:k793.CrossRefGoogle Scholar
  12. 12.
    Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med. 2018;168:121–30.CrossRefGoogle Scholar
  13. 13.
    Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391:933.CrossRefGoogle Scholar
  14. 14.
    Ferreira M, Pichon E, Carmier D, Bouquet E, Pageot C, Bejan-Angoulvant T, et al. Coronary toxicities of anti-PD-1 and anti-PD-L1 immunotherapies: a case report and review of the literature and international registries. Targ Oncol. 2018;13:509–15.CrossRefGoogle Scholar
  15. 15.
    Centanni M, Moes DJAR, Troconiz IF, Ciccolini J, van Hasselt JGC. Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors. Clin Pharmacokinet. 2019.  https://doi.org/10.1007/s40262-019-00748-2.
  16. 16.
    Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci. 2013;10:796–803.CrossRefGoogle Scholar
  17. 17.
    Giezen TJ, Mantel-Teeuwisse AK, Meyboom RH, Straus SM, Leufkens HG, Egberts TC. Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase. Drug Saf. 2010;33:865–78.CrossRefGoogle Scholar
  18. 18.
    Cutroneo PM, Isgro V, Russo A, Ientile V, Sottosanti L, Pimpinella G, et al. Safety profile of biological medicines as compared with non-biologicals: an analysis of the italian spontaneous reporting system database. Drug Saf. 2014;37:961–70.CrossRefGoogle Scholar
  19. 19.
    Gouverneur A, Claraz P, Rousset M, Arnaud M, Fourrier-Reglat A, Pariente A, et al. Comparative safety of targeted therapies for metastatic colorectal cancer between elderly and younger patients: a study using the international pharmacovigilance database. Target Oncol. 2017;12:805–14.CrossRefGoogle Scholar
  20. 20.
    Araujo AGS, Borba HHL, Tonin FS, Lenzi L, Venson R, Pontarolo R, et al. Safety of biologics approved for the treatment of rheumatoid arthritis and other autoimmune diseases: a disproportionality analysis from the FDA adverse event reporting system (FAERS). BioDrugs. 2018;32:377–90.CrossRefGoogle Scholar
  21. 21.
    Raschi E, Poluzzi E, Salvo F, Pariente A, De Ponti F, Marchesini G, et al. Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: what a clinician should know on disproportionality analysis of spontaneous reporting systems. Nutr Metab Cardiovasc Dis. 2018;28:533–42.CrossRefGoogle Scholar
  22. 22.
    Fukazawa C, Hinomura Y, Kaneko M, Narukawa M. Significance of data mining in routine signal detection: analysis based on the safety signals identified by the FDA. Pharmacoepidemiol Drug Saf. 2018;27:1402–8.CrossRefGoogle Scholar
  23. 23.
    Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther. 2013;93:539–46.CrossRefGoogle Scholar
  24. 24.
    Poluzzi E, Raschi E, Piccinni C, De Ponti F. Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS). In: Karahoca A, editor. Data mining applications in engineering and medicine. Croatia: InTech; 2012. p. 265–302.Google Scholar
  25. 25.
    Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18:427–36.CrossRefGoogle Scholar
  26. 26.
    Tuccori M, Montagnani S, Capogrosso-Sansone A, Mantarro S, Antonioli L, Fornai M, et al. Adverse reactions to oncologic drugs: spontaneous reporting and signal detection. Expert Rev Clin Pharmacol. 2015;8:61–75.CrossRefGoogle Scholar
  27. 27.
    Slattery J, Alvarez Y, Hidalgo A. Choosing thresholds for statistical signal detection with the proportional reporting ratio. Drug Saf. 2013;36:687–92.CrossRefGoogle Scholar
  28. 28.
    Hauben M, Hung E, Wood J, Soitkar A, Reshef D. The impact of database restriction on pharmacovigilance signal detection of selected cancer therapies. Ther Adv Drug Saf. 2017;8:145–56.CrossRefGoogle Scholar
  29. 29.
    Bragge P, Clavisi O, Turner T, Tavender E, Collie A, Gruen RL. The Global Evidence Mapping Initiative: scoping research in broad topic areas. BMC Med Res Methodol. 2011;11:92.CrossRefGoogle Scholar
  30. 30.
    Baraibar I, Melero I, Ponz-Sarvise M, Castanon E. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer. Drug Saf. 2019.  https://doi.org/10.1007/s40264-018-0774-8.
  31. 31.
    Khoja L, Day D, Wei-Wu CT, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28:2377–85.CrossRefGoogle Scholar
  32. 32.
    Xu C, Chen YP, Du XJ, Liu JQ, Huang CL, Chen L, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ. 2018;363:k4226.CrossRefGoogle Scholar
  33. 33.
    Ali AK, Watson DE. Pharmacovigilance assessment of immune-mediated reactions reported for checkpoint inhibitor cancer immunotherapies. Pharmacotherapy. 2017;37:1383–90.CrossRefGoogle Scholar
  34. 34.
    Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4:1721–8.CrossRefGoogle Scholar
  35. 35.
    Ji HH, Tang XW, Dong Z, Song L, Jia YT. Adverse event profiles of anti-CTLA-4 and anti-PD-1 monoclonal antibodies alone or in combination: analysis of spontaneous reports submitted to FAERS. Clin Drug Investig. 2019.  https://doi.org/10.1007/s40261-018-0735-0.
  36. 36.
    Macia-Martinez MA, de Abajo FJ, Roberts G, Slattery J, Thakrar B, Wisniewski AF. An empirical approach to explore the relationship between measures of disproportionate reporting and relative risks from analytical studies. Drug Saf. 2016;39:29–43.CrossRefGoogle Scholar
  37. 37.
    Sosa A, Lopez CE, Simon OC, Karachaliou N, Rosell R. Clinical assessment of immune-related adverse events. Ther Adv Med Oncol. 2018;10:1758835918764628.CrossRefGoogle Scholar
  38. 38.
    Suzman DL, Pelosof L, Rosenberg A, Avigan MI. Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents. Liver Int. 2018;38:976–87.CrossRefGoogle Scholar
  39. 39.
    De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol. 2018;68:1181–90.CrossRefGoogle Scholar
  40. 40.
    Wang W, Lie P, Guo M, He J. Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis of published data. Int J Cancer. 2017;141:1018–28.CrossRefGoogle Scholar
  41. 41.
    Gelsomino F, Vitale G, D’Errico A, Bertuzzi C, Andreone P, Ardizzoni A. Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. Ann Oncol. 2017;28:671–2.CrossRefGoogle Scholar
  42. 42.
    Gelsomino F, Vitale G, Ardizzoni A. Immune-mediated cholangitis: is it always nivolumab’s fault? Cancer Immunol Immunother. 2018;67:1325–7.CrossRefGoogle Scholar
  43. 43.
    Kawakami H, Tanizaki J, Tanaka K, Haratani K, Hayashi H, Takeda M, et al. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs. 2017;35:529–36.CrossRefGoogle Scholar
  44. 44.
    Kashima J, Okuma Y, Shimizuguchi R, Chiba K. Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report. Cancer Immunol Immunother. 2018;67:61–5.CrossRefGoogle Scholar
  45. 45.
    Gelsomino F, Vitale G, Ardizzoni A. A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event. Invest New Drugs. 2018;36:144–6.CrossRefGoogle Scholar
  46. 46.
    Ogawa K, Kamimura K, Terai S. Anti-programmed cell death-1 immunotherapy-related secondary sclerosing cholangitis. Hepatology. 2018;69:914–6.CrossRefGoogle Scholar
  47. 47.
    Noda-Narita S, Mizuno S, Noguchi S, Watanabe K, Nakai Y, Koike K, et al. Development of mild drug-induced sclerosing cholangitis after discontinuation of nivolumab. Eur J Cancer. 2019;107:93–6.CrossRefGoogle Scholar
  48. 48.
    Bonkovsky HL, Kleiner DE, Gu J, Odin JA, Russo MW, Navarro VM, et al. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology. 2017;65:1267–77.CrossRefGoogle Scholar
  49. 49.
    Misu T, Kortepeter CM, Munoz MA, Wu E, Dal Pan GJ. An evaluation of “drug ineffective” postmarketing reports in drug safety surveillance. Drugs Real World Outcomes. 2018;5:91–9.CrossRefGoogle Scholar
  50. 50.
    Juhlin K, Karimi G, Ander M, Camilli S, Dheda M, Har TS, et al. Using VigiBase to identify substandard medicines: detection capacity and key prerequisites. Drug Saf. 2015;38:373–82.CrossRefGoogle Scholar
  51. 51.
    Trippe ZA, Brendani B, Meier C, Lewis D. Identification of substandard medicines via disproportionality analysis of individual case safety reports. Drug Saf. 2017;40:293–303.CrossRefGoogle Scholar
  52. 52.
    Inacio P, Cavaco A, Airaksinen M. The value of patient reporting to the pharmacovigilance system: a systematic review. Br J Clin Pharmacol. 2017;83:227–46.CrossRefGoogle Scholar
  53. 53.
    Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res. 2017;23:1920–8.CrossRefGoogle Scholar
  54. 54.
    Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;33:3541–3.CrossRefGoogle Scholar
  55. 55.
    Sato K, Akamatsu H, Murakami E, Sasaki S, Kanai K, Hayata A, et al. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer. 2018;115:71–4.CrossRefGoogle Scholar
  56. 56.
    Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol. 2018;4:374–8.CrossRefGoogle Scholar
  57. 57.
    Teraoka S, Fujimoto D, Morimoto T, Kawachi H, Ito M, Sato Y, et al. Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: a prospective cohort study. J Thorac Oncol. 2017;12:1798–805.CrossRefGoogle Scholar
  58. 58.
    Michel C, Scosyrev E, Petrin M, Schmouder R. Can disproportionality analysis of post-marketing case reports be used for comparison of drug safety profiles? Clin Drug Investig. 2017;37:415–22.CrossRefGoogle Scholar
  59. 59.
    Oshima Y, Tanimoto T, Yuji K, Tojo A. EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer. JAMA Oncol. 2018;4:1112–5.CrossRefGoogle Scholar
  60. 60.
    Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19:1579–89.CrossRefGoogle Scholar
  61. 61.
    Arora A, Jalali RK, Vohora D. Relevance of the Weber effect in contemporary pharmacovigilance of oncology drugs. Ther Clin Risk Manag. 2017;13:1195–203.CrossRefGoogle Scholar
  62. 62.
    Trifiro G, Sultana J, Bate A. From big data to smart data for pharmacovigilance: the role of healthcare databases and other emerging sources. Drug Saf. 2018;41:143–9.CrossRefGoogle Scholar
  63. 63.
    Kibbelaar RE, Oortgiesen BE, van der Wal-Oost AM, Boslooper K, Coebergh JW, Veeger NJGM, et al. Bridging the gap between the randomised clinical trial world and the real world by combination of population-based registry and electronic health record data: a case study in haemato-oncology. Eur J Cancer. 2017;86:178–85.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Emanuel Raschi
    • 1
    Email author
  • Alessandra Mazzarella
    • 1
  • Ippazio Cosimo Antonazzo
    • 1
  • Nicolò Bendinelli
    • 1
  • Emanuele Forcesi
    • 1
  • Marco Tuccori
    • 2
  • Ugo Moretti
    • 3
  • Elisabetta Poluzzi
    • 1
  • Fabrizio De Ponti
    • 1
  1. 1.Pharmacology Unit, Department of Medical and Surgical SciencesAlma Mater Studiorum, University of BolognaBolognaItaly
  2. 2.Unit of Adverse Drug Reactions Monitoring, Tuscan Regional Centre of PharmacovigilanceUniversity Hospital of PisaPisaItaly
  3. 3.Department of Public Health and Community MedicineUniversity of VeronaVeronaItaly

Personalised recommendations